Status:
COMPLETED
A Study Of BOTOX For The Treatment Of Glabellar Lines
Lead Sponsor:
GlaxoSmithKline
Conditions:
Glabellar Lines
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This is a Multicenter, double-blind, randomized, placebo-controlled, parallel-group comparative study to confirm the efficacy and safety of BOTOX 20 units single injection for the Chinese patients wit...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Male and female adult with Glabellar lines of at least moderate severity at maximum frown by investigator's assessment.
- Exclusion criteria:
- Patients with systemic nerve conduction junction disorder or patients with infection or other skin disease/surgery at injection sites will not be eligible.
- Patient with severe complications related to heart, kidney, liver disease or respiratory system will not be eligible.
Exclusion
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 9 2007
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT00408785
Start Date
November 1 2006
End Date
May 9 2007
Last Update
May 31 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Beijing, China, 100034
2
GSK Investigational Site
Beijing, China, 100036
3
GSK Investigational Site
Beijing, China, 100853
4
GSK Investigational Site
Shanghai, China, 200040